533 related articles for article (PubMed ID: 26483088)
1. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
7. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
9. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
[TBL] [Abstract][Full Text] [Related]
10. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
[TBL] [Abstract][Full Text] [Related]
11. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.
Sah BR; Burger IA; Schibli R; Friebe M; Dinkelborg L; Graham K; Borkowski S; Bacher-Stier C; Valencia R; Srinivasan A; Hany TF; Mu L; Wild PJ; Schaefer NG
J Nucl Med; 2015 Mar; 56(3):372-8. PubMed ID: 25678494
[TBL] [Abstract][Full Text] [Related]
13. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
14. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
15. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
16. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors.
Mu L; Honer M; Becaud J; Martic M; Schubiger PA; Ametamey SM; Stellfeld T; Graham K; Borkowski S; Lehmann L; Dinkelborg L; Srinivasan A
Bioconjug Chem; 2010 Oct; 21(10):1864-71. PubMed ID: 20857927
[TBL] [Abstract][Full Text] [Related]
18. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.
Hara T; Kosaka N; Kishi H
J Nucl Med; 2002 Feb; 43(2):187-99. PubMed ID: 11850483
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
[TBL] [Abstract][Full Text] [Related]
20. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
